Clinical development of platinum complexes in cancer therapy: An historical perspective and an update

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1522-1534

  Lebwohl, D ^a   Canetta, R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cancer therapy; Clinical development; Historical Perspective; Platinum coordination complexes; Update

Indexed keywords

1,2 DIAMINOCYCLOHEXANE ALPHA ACETYL GAMMA METHYLTETRONATE PLATINUM II; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPLATAM; EPTAPLATIN; IPROPLATIN; LOBAPLATIN; MIBOPLATIN; NEDAPLATIN; OXALIPLATIN; PLATINUM COMPLEX; SATRAPLATIN; SEBRIPLATIN; TETRAPLATIN; TRK 710; UNCLASSIFIED DRUG; ZENIPLATIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG STRUCTURE; HEAD AND NECK CANCER; HUMAN; LIVER TOXICITY; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS;

EID: 0032168673     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00224-X     Document Type: Review

References (132)

1. 1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698-699.
2. 2. Werner A. Beitrag zur konstitution anorganischer verbindingen. Zeiter Anorgan Chem 1893, 3, 207-330.
3. 3. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985, 55, 2303-2316.
4. 4. Hill JM, Speer RJ, Loeb E, MacLellan A, Hill NO, Khan A. Clinical experience with cisplatinous diammine dichloride (PPD). In Hejzlar M, ed. Advances in Antimicrobial and Antineoplastic Chemotherapy. Prague, Urban & Schwartzenberg, 1971, 255-257.
5. 5. Ash DC. Cis-platinum (II) diamminedichloride: clinical review of a new cancer chemotherapeutic agent. J Clin Hem Oncol 1980, 10, 55-62.
6. 6. Talley RW, O'Bryan RM, Gutterman J, Brownlee RW, McCredie KB. Clinical evaluations of toxic effects of cis-platinum (II) diamminedichloride. A phase I clinical trial. In Connors TA, Roberts JJ, eds. Platinum Coordination Complexes in Cancer Chemotherapy. Heidelberg, Springer, 1974, 160-166.
7. 7. Higby DJ, Wallace HJ Jr, Albert D, et al. Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol 1974, 112, 100-104.
8. 8. Wiltshaw E, Carr B. Cis-platinumdiamminedichloride. In Connors TA, Roberts JJ, eds. Platinum Coordination Complexes in Cancer Chemotherapy. Heidelberg, Springer, 1974, 178-182.
9. 9. Hayes D, Cvitkovic E, Golberg R, Scheiner E, Krakoff IH. Amelioration of renal toxicity of high dose cis-platinum diammine dichloride (CPDD) by mannitol induced diuresis. Proc Am Assoc Cancer Res 1976, 67, 169.
10. 10. Merrin C. A new method to prevent toxicity with high doses of cis diammine platinum (therapeutic efficacy in previously treated widespread and recurrent testicular tumors). Proc Am Soc Clin Oncol 1976, 12, 243.
11. 11. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87, 293-298.
12. 12. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Brit Med J 1991, 303, 884-893.
13. 13. Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Brit Med J 1995, 311, 899-909.
14. 14. Von Hoff DD, Rozencweig M. Cis-diamminedichloroplatinum (II): a metal complex with significant anticancer activity. In Garattini S, Goldin A, Hawking F, Kodin JJ, eds. Advances in Pharmacology and Chemotherapy. New York, Academic Press, 1979, 16, 273-298.
15. 15. Shiratori O, Kasai H, Uchida N, Totani T, Saito K. Antitumor activity of 254-S, a platinum complex, in rodents. Proc Int Congress Chemotherapy 1985, 14, 23-26.
16. 16. Ariyoshi Y, Ota K, Wakui A, et al. Phase I study of (glycolato-0,0′) diammine platinum (II) (254-5). Proc Am Soc Clin Oncol 1988, 7, 59.
17. 17. Sasaki Y, Amano T, Morita M, et al. Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 3751010) administered by 5-day continuous intravenous infusion. Cancer Res 1991, 51, 1472-1477.
18. 18. Ota K, Miyake H, Inuyama I, et al. Clinical evaluation of cisdiammine (glycolato) plat 254-S, a new anticancer platinum complex. Proc NCI-EORTC Symp New Drugs in Cancer Therapy 1991, 7, 340.
19. 19. Furuse K, Kimura I, Niitani H, Sakuma A. A randomized comparative study of 254-S/vindesine (VDS) vs. cisplatin (CDDP)/VDS for advanced non-small cell lung cancer (NSCLC). Lung Cancer 1993, 9, 122.
20. 20. Gorbunova VA, Smirnova NB, Orel NF, Konovalova AL, Singin AS. A phase I and pharmacokinetic trial of cycloplatam in patients with refractory solid tumors. Proc NCI-EORTC Symp New Drugs in Cancer Therapy 1994, 8, 215.
21. 21. Gorbunova VA, Smirnova NB, Orel NE. Phase II of cycloplatam in advanced ovarian carcinoma. Proc Int Congress on Anti-Cancer Chemother 1995, 5, 382.
22. 22. Ayrapetian LG. New analog of platinum-cycloplatam - treatment of breast cancer. Proc Int Congress on Anti-Cancer Chemother 1996, 6, 403.
23. 23. Drees M, Sengler WM, Hendriks HR, Kelland LR, Fiebig HH. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Eur J Cancer 1995, 31A, 356-361.
24. 24. Kim NK, Bang Y-J, Heo DS, et al. A phase I clinical and pharmacokinetic study of SKI 2053 R, a new platinum analog in patients with malignancies. Proc Am Soc Clin Oncol 1995, 14, 479.
25. 25. Kim NK, Im SA, Jung CW, et al. An active new platinum analog SKI 2053 R in patients with advanced gastric adenocarcinoma: phase II clinical trial. Proc Am Soc Clin Oncol 1997, 16, 294a.
26. 26. Hill JM, Speer RJ. Organo-platinum complexes as antitumor agents. Anticancer Res 1982, 2, 173-186.
27. 27. Muggia FM, Wolpert-De Filippes MK, Ribaud P, Mathe G. Clinical results with cisplatin analogs. In Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin, Current Status and New Developments. New York, Academic Press, 1980, 517-527.
28. 28. Thatcher N, Sharma H, Harrison R, et al. Blood clearance of three radioactively labelled platinum complexes. Cancer Chemother Pharmacol 1982, 9, 13-16.
29. 29. Owens SE, Thatcher N, Sharma H, et al. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis(isopropylamine) platinum (IV), cis-dichloro-bis-cycloproylamine platinum (II), and cis-diammine, 1,1-cyclobutanedycarboxylate platinum (II) in patients with malignant disease, using a gamma camera. Cancer Chemother Pharmacol 1985,14, 253-257.
30. 30. Pinedo HM, Ten Bokkel Huinink WW, Van Der Vijgh WJF, et al. Phase I study of ethylenediaminoplatinum (II) malonate (JM-40). Proc Am Soc Clin Oncol 1984, 3, 40.
31. 31. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Reviews 1985, 12(Suppl A), 21-33.
32. 32. Rose WC, Schurig JE. Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Reviews 1985, 12(Suppl A), 1-19.
33. 33. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982, 9, 140-147.
34. 34. Canetta R, Bragman K, Smaldone L, Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Reviews 1988, 15(Suppl B), 17-32.
35. 35. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992, 10, 520-528.
36. 36. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
37. 37. Fish RG, Shelley MD, Griffiths H, Mason M, Adams M, James K. A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count. Anti Cancer Drugs 1994, 5, 527-532.
38. 38. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphologies and biological patient characteristics. J Natl Cancer Inst 1995, 87, 573-580.
39. 39. Kavanagh JJ. Carboplatin in refractory epithelial ovarian cancer. In Bunn PA Jr, Canetta R, Ozols RF, Rozencweig M, eds. Carboplatin, Current Perspectives and Future Directions. Philadelphia, W.B. Saunders, 1990, 141-152.
40. 40. Kearns CM, Belani CP, Erkmen K, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 1995, 14, 170.
41. 41. Creaven PJ, Raghavan D, Perez RP, et al. Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Sem Oncol 1996, 6(Suppl 16), 26-31.
42. 42. Fiebig HH, Mross K, Henss H, Aulenbocher P, Quiessler W. Phase I study of the new platinum complex D19466 on a single intermittent schedule. Eur J Cancer 1991, Suppl, S197.
43. 43. Gietema JA, deVries EGE, Sleijfer DT, et al. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 1993, 67, 396-401.
44. 44. Gietema JA, Guchelaar H-J, deVries EGE, Aulenbacher P, Sleijfer DT, Mulder NH. A phase I study of lobaplatin (D-19466) administered by 72h continuous infusion. Anti Cancer Drugs 1993, 4, 51-55.
45. 45. Gietema JA, Veldhuis G-J, Guchelaar H-J, et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Brit J Cancer 1995, 71, 1302-1307.
46. 46. Kavanagh JJ, Finnegan MB, Edwards CL, et al. A trial of lobaplatin (D-19466) in platinum resistant epithelial ovarian cancer. Proc Am Soc Cancer Res 1995, 36, 401.
47. 47. Dejardin M, Armand JP, Chevallier B, et al. A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Invest New Drugs 1995, 13, 253-255.
48. 48. Feibig HH. Phase I and II studies with lobaplatin. Proc Int Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1995, 7, S127.
49. 49. Sternberg CN, de Mulder P, Fossa S, et al. Lobaplatin in advanced urothelial tract turners. Ann Oncol 1997, 8, 695-696.
50. 50. Schmoll HJ, Kohne CH, Papageorgiou E, et al. Single agent lobaplatin is active in patients with esophageal squamous cell carcinoma. A phase II evaluation. Proc Am Soc Clin Oncol 1995, 14, 201.
51. 51. Rolland F, Douillard JY, Adenis A, et al. Lobaplatin in combination with 5-fluorouracil in patients with esophageal carcinoma: a phase I/II feasibility study. Proc Int Congress on Anti-Cancer Treatment 1996, 6, 320.
52. 52. Hlavka JJ, Bitha P, Carvajal SG, et al. Two new water soluble platinum compounds - CL286,558 and CL287,110. In Nicolini M, Bandoli G, eds. Platinum and other Metal Coordination Complexes in Cancer Chemotherapy. Padua, Cleup, 1987, 357-358.
53. 53. Ceulemans F, Duprez P, Vindevogel A, et al. Enloplatin (CL 287,110): phase I study in patients with advanced solid tumors. Proc Intl Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1991, 7, 168.
54. 54. Kudelka A, Edwards C, Freidman R, et al. Phase II study of enloplatin for patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1993, 12, 269.
55. 55. Dodion PF, de Valeriola D, Crespeigne N, et al. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann Oncol 1991, 2, 589-596.
56. 56. Olver I, Green M, Peters W, et al. A phase II of zeniplatin in metastatic melanoma. Am J Clin Oncol 1995, 18, 56-58.
57. 57. Willemse PHB, Gietema JA, Mulder NH, et al. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer 1993, 29A, 359-362.
58. 58. Markman M, DeMarco LC, Birkhofer M, et al. Phase II trial of zeniplatin (CL 286558), a new platinum compound, in patients with advanced ovarian cancer previously treated with organo-platinum-based therapy. J Cancer Res Clin Oncol 1993, 119, 234-236.
59. 59. Kraker AJ, Moore CW, Leopold WR, Takahashi K. Preclinical characterization of the in vitro and in vivo activity of [1,1′-cyclobutane dicarboxylato (2-)-0,0′](2-methyl 1-1,4-butanediamine-N,N′) Pt (NK-121/CI-973). Proc Am Assoc Cancer Res 1988, 29, 344.
60. 60. Hino M, Niitani H, Hasegawa K, et al. Phase I study of new platinum compound, NK121. In Rubinstein E, Adam D, eds. Recent Advances in Chemotherapy. Jerusalem, E. Lewin-Epstein Ltd., 1989, 745.1-745.2.
61. 61. Theriault RL, Cohen IA, Esparza L, Kowal C, Raber MN. Phase I clinical evaluation of [SP-4-3 (R)]-{1,1′ cyclobutanedicarboxylato (2-)] (2-methyl-1,4-butanediammine-N,N′) platinum in patients with metastatic solid tumors. Cancer Chemother Pharmacol 1993, 31, 333-337.
62. 62. O'Dwyer PJ, Hudes GR, Walczak J, et al. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. Cancer Res 1992, 52, 6746-6753.
63. 63. Roberts J, Kudelka A, Spriggs D, et al. Phase II study of CI-973 in advanced ovarian cancer. Proc An Soc Clin Oncol 1994, 13, 269.
64. 64. Ogawa M. Clinical trials of 254-S, NK121, and TRK-710. Proc Int Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1995, 7, S.129.
65. 65. Akamatsu K, Endo K, Matsumoto T, et al. Toxicological and tumoricidal evaluations of a new platinum complex, (-)-R-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato) platinum (II) monohydrate, in rats. Jpn J Cancer Res 1991, 82, 724-731.
66. 66. Taguchi T. Clinical trials of oxaliplatin and DWA 2114R. Proc Int Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1995, 7, S.130.
67. 67. Sasaki H, Kato T, Terashima Y, Nishimura H, Ota K. Phase II trial of DWA2114R for ovarian cancer. J Cancer Res Clin Oncol 1990, 116(Suppl), 526.
68. 68. Kato T, Yakushiji M, Nishimura H, et al. Phase III study of DWA2114R for ovarian cancer. Jpn J Cancer Chemother 1992, 19, 1285-1293.
69. 69. Mathé G, Kidani Y, Noji M, Maral R, Bourut C, Chenu E. Antitumor activity of 1-OHP in mice. Cancer Letters 1985, 27, 135-143.
70. 70. Pendyala L, Creaven PJ, Shah G, Molnar MV, Grandjean EM. In vitro cytotoxity studies of oxaliplatin in human tumor cell lines. Proc Am Assoc Cancer Res 1991, 32, 410.
71. 71. Mathé G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexane oxalatoplatinum (1-OHP). Biomedicine & Pharmacotherapy 1986, 40, 372-376.
72. 72. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 5, 299-303.
73. 73. Eriguchi M, Sekiguchi M, Fujii Y, et al. Clinical study for a new platinum complex 1-OHP: oxalato (1-1, 2-diaminocyclohexane) platinum (II) against solid tumors. Proc NCI-EORTC Symposium on New Drugs in Cancer Therapy 1991, 7, 343.
74. 74. Caussanel J-P, Levi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82, 1046-1050.
75. 75. Rotarski M, Brienza S, Gastiaburu J, et al. Oxaliplatin (1-OHP): a new platinum analog: active in refractory/relapsed intermediate and low grade non-Hodgkin lymphoma. Proc Am Soc Clin Oncol 1993, 12, 375.
76. 76. Garufi C, Nistico C, Brienza S, et al. Oxaliplatin (1-OHP) activity in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 1997, 16, 170a.
77. 77. Gastiaburu J, Misset JL, Brienza S, et al. Early phase II trial of trans-1-diammino cyclohexane (1-OHP) in malignant melanoma, advanced ovarian cancer, low grade non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res 1992, 33, 538.
78. 78. Monnet I, Brienza S, Voisin S, et al. Phase II study of oxaliplatin (1-OHP, transplatin) in patients with advanced non small cell lung cancer: preliminary results. Proc NCI-EORTC Symposium on New Drugs in Cancer Therapy 1994, 8, 224.
79. 79. Degardin M, Cappelaere P, Krakowski I, Conroy T, Rotarski M, Brienza S. Phase II trial of oxaliplatin (1-OHP) in locoregional advanced, recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 1994, 5(Suppl 8), 119.
80. 80. Maugard-Louboutin C, Fumoleau P, Ibrahim N, et al. Preliminary phase II trial of oxaliplatin (1-OHP) in malignant astrocytomas. Eur J Cancer 1993, 29A(Suppl 6), S191.
81. 81. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996, 7, 1065-1070.
82. 82. Levi F, Machover D, Marty M, et al. Oxaliplatin (1-OHP): summary of results in advanced colorectal cancer. Eur J Cancer 1995, 31A(Suppl 5), 154.
83. 83. de Braud F, Munzone E, Nolé F, et al. Oxaliplatin (1-OHP) as a second line treatment in metastatic colorectal cancer patients clinically resistant to fluorouracil. Proc Am Assoc Cancer Res 1997, 38, 520.
84. 84. Becouarn Y, Ychou M, Ducreux M, et al. Oxaliplatin (1-OHP) as first-line chemotherapy in metastatic colorectal cancer patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1997, 16, 229a.
85. 85. Levi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86, 1608-1617.
86. 86. Giacchetti S, Zidani R, Perpoint B, et al. Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997, 16, 229a.
87. 87. Misset JL, Chollet P, Vennin P, et al. Multicentre phase II-III trial of oxaliplatin versus cisplatin, both in association with cyclophosphamide, in the treatment of advanced ovarian cancer: toxicity efficacy results. Proc Am Soc Clin Oncol 1997, 16, 354a.
88. 88. Perez-Soler R, Khokhar AR, Lautersztain J, et al. Clinical development of liposomal platinum. J of Liposome Res 1990, 1, 437-449.
89. 89. Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al. Phase I clinical and pharmacological study of liposome-entrapped cisbis-neodexanoato-trans-R,R-1,2-diaminocyclohexane platinum (II). Cancer Res 1990, 50, 4254-4259.
90. 90. Perez-Soler R, Siddik ZH, Chase J, Al-Baker S, Khokar AR, Pazdur R. Phase I clinical and pharmacology study of liposome-entrapped cis-bis-neodexanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (1-NDDP). Proc Am Soc Clin Oncol 1993, 12, 153.
91. 91. Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped (L-NDDP) administered intrapleurally in patients with malignant pleural effusions. Proc Am Soc Clin Oncol 1996, 15, 492.
92. 92. Mutoh M, Matsushita Y, Saito Y, Adachi Y, Imanishi H. Antitumor activity of TRK-710, a new platinum complex having activity against cisplatin-resistant tumours. Proc Am Assoc Cancer Res 1993, 34, 399.
93. 93. Inoue S, Mizuno S. Cytometric characterization of cisplatin and a new platinum analog, TRK-710. Proc Int Congress on Anti-Cancer Chemotherapy 1995, 5, 214.
94. 94. Khan A, Speer RJ, Ridgway H, et al. Pre-clinical and phase I clinical trial with bis (pyruvato) 1,2-diaminocyclohexane platinum (II). In Hacker MP, Douple EB, Krakoff IH, eds. Platinum Coordination Complexes in Cancer Chemotherapy. Boston, Martinus Nijhoff, 1983, 255.
95. 95. Macquet J-P, Lios S, Armand J-P. Pharmacological and pre-clinical toxicological studies of 1,2-diaminocyclohexane (isocitrato) platinum (II). Cancer Res 1984, 44, 3736-3743.
96. 96. Armand J-P, Fontana X, Benhamed M, Ruffié P. New platinum analogs. Proc ECCO 1985, 3, 59.
97. 97. Kelsen DP, Seher J, Burchenal J. Phase I and early phase II trials of 4′carboxyphthalato (1,2 diaminocyclohexane) platinum (II). In Hacker MP, Douple EB, Krakoff IH, eds. Platinum Coordination Complexes in Cancer Chemotherapy. Boston, Martinus Nijhoff, 1984, 310-320.
98. 98. Burchenal JH, Kalaher K, O'Toole T, Chisholm J. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res 1977, 37, 3455-3457.
99. 99. de Jon WH, Steerenberg PA, Vos JG, et al. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexane platinum (II) sulfate, and of cis-diammine dichloroplatinum (II) in immunocytoma model in the LOU/M rat. Cancer Res 1983, 43, 4927-4934.
100. 100. Franks CR, Materman E, Nys G, et al. TN06 (1,1-diaminomethylcyclohexane sulphate platinum II, NSC 311056) in phase II trials. Proc ECCO 1985, 3, 84.
101. 101. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexane platinum (IV): an orally active platinum drug. Cancer Res 1993, 53, 2581-2586.
102. 102. Rose WC, Crosswell AR, Schruig JE, Casazza AM. Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 1993, 32, 197-203.
103. 103. Harrap KR. Initiatives with platinum and quinazoline-based antitumor molecules. Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995, 55, 2761-2768.
104. 104. Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997, 40, 51-56.
105. 105. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM-216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995, 36, 451-458.
106. 106. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997, 15, 2691-2700.
107. 107. Saraf N, Smith R, Brassard C, et al. Phase I trial of the oral platinum analog BMS-182751 (JM-216) in patients with refractory cancer. Proc Am Soc Clin Oncol 1996, 15, 485.
108. 108. Fujii H, Sasaki Y, Tomura T, Negoro S, Fukuoka M, Saijo N. A phase I and pharmacokinetic (PK) study of the oral platinum (Pt) analog JM216. Proc Am Soc Clin Oncol 1997, 16, 215a.
109. 109. Pagani O, Bauer J, Borner M, et al. Phase I study of the oral platinum derivative JM216 given daily for 14 days. Ann Oncol 1996, 7(Suppl 5), 125.
110. 110. Hoffman P, Masters G, Mauer A, et al. A phase I study of JM-216 with concomitant radiation therapy for patients with malignancies of the chest. Lung Cancer 1997, 19(Suppl 1), 71.
111. 111. Groen HJM, Smit EF, Bauer J, et al. A phase II study of oral platinum JM-216 as first-line treatment in small cell lung cancer. Proc Am Soc Clin Oncol 1996, 15, 378. Abstract.
112. 112. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997, 8, 604-606.
113. 113. Peereboom DM, Wood L, Connell C, et al. Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1997, 16, 339a.
114. 114. Miglietta L, Cannobbio L, Boocardo F. Assessment of response of carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995, 15, 2825-2828.
115. 115. Parker RJ, Vionnet JA, Bostick-Bruton F, Need E. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Cancer Res 1993, 53, 242-247.
116. 116. Christian MC. Overview of clinical results with ormaplatin. Proc Int Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1995, 7, S.128.
117. 117. Cleare MJ, Hydes PC, Walerbi BW, et al. Antitumor platinum complexes: relationship between chemical properties and activity. Biochimie 1978, 60, 835-850.
118. 118. Lee FH, Canetta R, Issell BF, Lenaz L. New platinum complexes in clinical trial. Cancer Treat Rev 1983, 10, 39-52.
119. 119. Wolpert-DeFilippes MK. Antitumor activity of cisplatin analogs. In Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin, Current Status and New Developments. New York, Academic Press, 1980, 183-192.
120. 120. Creaven PJ, Madajewicz S, Pendyala L, et al. Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine (IV) (CHIP). Cancer Treat Rep 1983, 67, 795-800.
121. 121. Bramwell VHC, Crowther D, O'Malley S, et al. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Cancer Treat Rep 1985, 69, 409-416.
122. 122. Sessa C, Vermorken J, Renard J, et al. Phase II study of iproplatin in advanced ovarian carcinoma. J Clin Oncol 1988, 6, 98-105.
123. 123. Weiss G, Green S, Alberts DS, et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group Study. Eur J Cancer 1991, 27, 135-13.
124. 124. Madajewicz S, Takita H, Creaven P, Canetta R, Plager J. Small cell carcinoma of the lung. Phase II study of iproplatin as the single agent and combination chemotherapy of iproplatin and etoposide. Proc Eur Conf Clin Oncol 1985, 3, 98.
125. 125. Cappelaere P, Guiochet N, Bastit PH, et al. Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung. Eur J Cancer 1993, 29, 1216.
126. 126. McGuire WP, Blessing JA, Hatch K, DiSaia PJ. A phase II study of CHIP in advanced squamous cell carcinoma of the cervix (A Gynecological Oncology Group Study). Invest New Drugs 1986, 4, 181-186.
127. 127. Seynaeve C, Rodenburg CJ, Von Leeuwen JTM, et al. Iproplatin (CHIP) as first-line chemotherapy in metastatic transitional cell carcinoma of the urinary tract. Proc Eur Conf Clin Oncol 1989, 5, P.0568.
128. 128. Granfortuna JM, Newman N, Ginsberg SJ, et al. Phase II study of iproplatin (CUT) in previously treated small-cell lung cancer. Am J Clin Oncol 1989, 12, 355-357.
129. 129. Franks CR, Nys G, Schultz HP, Schmoll HJ, Canetta R, Rozencweig M. Randomized phase II trial of carboplatin vs iproplatin in solid tumors. Proc Am Soc Clin Oncol 1986, 5, 129.
130. 130. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985, 12(Suppl A), 125-136.
131. 131. Trask C, Silverstone A, Ash CM, et al. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J Clin Oncol 1991, 9, 1131-1137.
132. 132. Gurney H, Crowther D, Anderson H, et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian cancer. Ann Oncol 1990, 1, 427-433.